NeoPharm CO. LTD (092730) — Cash Flow-to-Debt Ratio
NeoPharm CO. LTD (092730) has a Cash Flow-to-Debt Ratio of 0.31x as of September 2025, meaning its operating cash flow of ₩5.88 Billion could theoretically repay 0% of its total liabilities (₩18.97 Billion) in one year. Explore NeoPharm CO. LTD (092730) investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
NeoPharm CO. LTD Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for NeoPharm CO. LTD across 11 annual periods. Also explore NeoPharm CO. LTD balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for NeoPharm CO. LTD (2012–2024)
Year-by-year debt coverage analysis for NeoPharm CO. LTD. For market capitalisation and broader financial context, see NeoPharm CO. LTD (092730) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 1.20x | ₩18.63 Billion | ₩15.56 Billion | ▼ -10.2% |
| 2023 | 1.33x | ₩23.26 Billion | ₩17.43 Billion | ▼ -3.5% |
| 2022 | 1.38x | ₩18.16 Billion | ₩13.14 Billion | ▼ -16.5% |
| 2021 | 1.65x | ₩21.68 Billion | ₩13.10 Billion | ▲ +47.9% |
| 2020 | 1.12x | ₩17.07 Billion | ₩15.26 Billion | ▼ -0.8% |
| 2019 | 1.13x | ₩19.22 Billion | ₩17.05 Billion | ▼ -4.9% |
| 2018 | 1.19x | ₩16.18 Billion | ₩13.64 Billion | ▲ +1.5% |
| 2017 | 1.17x | ₩10.65 Billion | ₩9.11 Billion | ▲ +1.3% |
| 2016 | 1.15x | ₩9.16 Billion | ₩7.94 Billion | ▲ +47.4% |
| 2015 | 0.78x | ₩6.09 Billion | ₩7.79 Billion | ▲ +485.1% |
| 2012 | 0.13x | ₩564.34 Million | ₩4.22 Billion | — |